AbbVie Inc (ABBV)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 32.16% | 35.95% | 38.32% | 35.97% | 38.54% | 38.03% | 40.52% | 42.86% | 42.27% | 40.53% | 37.78% | 35.49% | 40.14% | 39.14% | 54.01% | 71.10% | 77.64% | 77.32% | 77.41% | 77.07% |
| Operating profit margin | 23.49% | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% |
| Pretax margin | 11.49% | 14.50% | 18.64% | 15.89% | 23.20% | 25.55% | 24.52% | 24.76% | 23.10% | 13.06% | 11.19% | 8.29% | 7.41% | 19.62% | 20.65% | 26.37% | 25.33% | 9.06% | 11.46% | 15.14% |
| Net profit margin | 8.95% | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% |
AbbVie Inc's profitability ratios have shown a general downward trend from Q1 2022 to Q4 2023.
The gross profit margin, which indicates the percentage of revenue that exceeds the cost of goods sold, has been declining gradually from 70.48% in Q2 2022 to 62.42% in Q4 2023. This trend suggests that AbbVie may be experiencing increasing costs relative to its revenue.
The operating profit margin, representing the percentage of revenue that remains after deducting operating expenses, has also seen a decline over the quarters, dropping from 33.01% in Q2 2022 to 24.59% in Q4 2023. This decrease indicates that AbbVie's operating expenses may have been rising at a faster rate than its revenue.
Similarly, the pretax margin, which reflects the company's profitability before accounting for taxes, has decreased from 24.54% in Q2 2022 to 11.51% in Q4 2023. This declining trend suggests that AbbVie's overall profitability has been eroding over the periods analyzed.
Lastly, the net profit margin, which shows the percentage of revenue that converts into net income, has also decreased significantly from 23.08% in Q3 2022 to 8.87% in Q4 2023. This decline could indicate challenges in managing expenses or declining sales growth.
Overall, the decreasing trend in AbbVie's profitability ratios over the quarters signals potential challenges in maintaining profitability and efficiency in the company's operations. Further analysis may be needed to identify the underlying factors contributing to these trends and to develop strategies to address them.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 9.47% | 11.06% | 12.84% | 12.02% | 13.05% | 12.52% | 12.15% | 12.94% | 12.23% | 11.15% | 10.51% | 7.88% | 7.55% | 7.73% | 7.31% | 14.89% | 14.57% | 11.08% | 12.47% | 11.43% |
| Return on assets (ROA) | 3.61% | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% |
| Return on total capital | 81.70% | 84.52% | 98.51% | 84.75% | 90.98% | 106.39% | 111.53% | 100.61% | 99.98% | 71.40% | 67.76% | 48.74% | 44.71% | 67.84% | 66.05% | — | — | — | — | — |
| Return on equity (ROE) | 46.94% | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — |
The profitability ratios of Abbvie Inc show a fluctuating trend over the past eight quarters. Operating return on assets (Operating ROA) has ranged from 9.91% to 13.97%, indicating the company's ability to generate operating income relative to its total assets has varied. Meanwhile, Return on assets (ROA) has ranged from 3.58% to 9.44%, reflecting the overall efficiency of the company in generating profits from its assets.
Return on total capital has shown variability between 19.15% and 24.56%, demonstrating Abbvie's ability to generate returns for both debt and equity holders. Return on equity (ROE) has shown significant fluctuations between 46.53% and 85.79%, indicating the company's ability to generate profits for its shareholders based on their equity investment.
Overall, the profitability ratios of Abbvie Inc reflect some degree of inconsistency in performance over the analyzed quarters, suggesting potential fluctuations in operational efficiency and profitability levels.